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Objectives: There are limited data available on the epidemiologyand prevalence ofmethicillin-resistant Staphylo-
coccus aureus (MRSA) in the human population that encode the recently described mecA homologue, mecC. To
address this knowledge gapwe undertook a prospective prevalence study in England to determine the prevalence
ofmecC among MRSA isolates.
Patients andmethods: Three hundred and thirty-five sequential MRSA isolates from individual patients were col-
lected from each of six clinical microbiology laboratories in England during 2011–12. Thesewere tested by PCR or
genome sequencing to differentiate those encodingmecA andmecC. mecC-positive isolates were further charac-
terized bymultilocus sequence typing, spa typing, antimicrobial susceptibility profile and detection of PBP2a using
commercially available kits.
Results: Nine out of the 2010 MRSA isolates tested were mecC positive, indicating a prevalence among MRSA in
England of 0.45% (95% CI 0.24%–0.85%). The remainder were mecA positive. Eight out of these nine mecC
MRSA isolates belonged to clonal complex 130, the other being sequence type 425. Resistance to non-b-lactam
antibioticswas rareamong thesemecCMRSA isolatesandallwerephenotypically identifiedasMRSAusingoxacillin
and cefoxitin according to BSACdisc diffusionmethodology. However, all ninemecC isolates gave a negative result
using three different commercial PBP2a detection assays.
Conclusions:mecCMRSAare currently rare amongMRSA isolated fromhumans in England and this study provides
an important baseline prevalence rate to monitor future changes, which may be important given the increasing
prevalence ofmecCMRSA reported in Denmark.
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Introduction
Staphylococcus aureus is a versatile, opportunistic pathogen able
tocauseawide rangeofdiseases inhumans, fromminor skin infec-
tions to severe illnesses such as septicaemia, toxic shock, endocar-
ditis and pneumonia. It is also able to colonize and infect a variety
of other host species, including farm and companion animals and
wildlife. The emergence and dissemination ofmethicillin-resistant
S. aureus (MRSA) since theearly1960shasposedamajorchallenge
to the treatment of S. aureus infections. Methicillin resistance in
S. aureus is conferred by the acquisition of one of several staphylo-
coccal cassette chromosomemec (SCCmec) elements,whichcarry
the mecA gene encoding a penicillin-binding protein homologue
(PBP2a) with reduced affinity for b-lactam antibiotics.1 We identi-
fied a novel mecA homologue, mecALGA251, encoded in a new
SCCmec element, designated type XI, among human and bovine
MRSA isolates in theUKandDenmark.2 ThismecAhomologue, sub-
sequently named mecC,1 exhibits only 69% identity at the DNA
level and 63% identity at the protein level to the previously
described mecA/PBP2a. As a result, it is not detectable by routine
mecA-specific PCR approaches or PBP2a slide agglutination tests.
mecC MRSA have now been isolated in small numbers from
humans and a wide range of other host species in several
European countries: Republic of Ireland,3 France,4 Sweden,5–7 the
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Netherlands,8 Germany,8–11 Austria,12 Switzerland,13 Finland,14
Spain,15 Norway16 and Belgium.17,18 However, the origin and epi-
demiology of these strains are poorly understood and there are
limited data on their prevalence. Importantly, the frequency of
mecCMRSA has increased significantly in Denmark since 2003.19
To provide baseline data for future surveillance in the UK, we
undertookaprospective surveyofa total of2010MRSA isolatescol-
lected from six clinical microbiology laboratories in England and
screened these by PCR or genome sequencing formecA andmecC.
Methods
Isolate collection and assessment of mec gene status
Three hundred and thirty-five sequential MRSA isolates from individual
patients were identified according to local procedures from screening and
clinical samples at five hospital clinical microbiology laboratories from
October 2011 to August 2012 (Table 1). These were sent to Cambridge for
PCRdetectionofmecAandmecC, asdescribedpreviously.17 Thesewere iso-
latesdrawnfromhospitalsandotherhealthcareproviders in thecatchment
area of each laboratory, including community-based general practitioners.
Methicillin resistancewasbasedonphenotypic resistance (cefoxitindiscdif-
fusion, Vitek 2 or chromogenic agars) in all cases and not onmolecular de-
tection of mecA or PBP2a. Isolates from a sixth hospital (Addenbrooke’s
Hospital, Cambridge; Table 1) were collected as above and genome
sequenced as part of an independent study. These were not assessed by
PCR but by interrogation of their genome sequences using BLAST analysis
to identifymecAandmecCMRSA isolateswith confirmationof thepresence
of femB as a speciesmarker of S. aureus. The analysis of 2010 isolates pro-
videsthepower todetectmecCMRSAprevalenceata lower limitof0.05%at
the 95% confidence level.
Antimicrobial susceptibility testing and slide
agglutination for PBP2a
AllmecCMRSA isolateswereanalysedusing theVitek2 system (bioMe´rieux,
Basingstoke, UK). In brief, suspensions of cultures were made in 0.45%
sodiumsolution fromgrowth on Columbia bloodagar, adjusted to a turbid-
ity equivalent to that of a 0.5 McFarland standard and used to load the test
cards,whichwereused inaccordancewith themanufacturer’s instructions.
The StaphAST-P620 cardwas automatically filled, sealed and inserted into
the Vitek 2 reader–incubator module (incubation temperature 378C), and
fluorescence measurements were performed every 15 min for up to 18 h.
Cefoxitin and oxacillin resistances were also assayed by disc diffusion fol-
lowing BSAC guidelines (version 11.1 May 2012) and the MICs of cefoxitin
and oxacillin were determined using Etest strips (bioMe´rieux). All mecC
MRSA isolates identified were tested with three commercially available
PBP2a detection assays according to the manufacturers’ instructions: the
MastalexTM MRSATest (Mast Diagnostics, Bootle, UK), the Penicillin Binding
Protein (PBP2′) Latex Agglutination Test (Oxoid, Basingstoke, UK) and the
AlereTM PBP2a Culture Colony Test (Alere Ltd, Stockport, UK). The mecA-
positive MRSA strain NCTC12493 was used as a positive control.
Genome sequencing and spa typing
All mecC MRSA isolates underwent whole genome sequencing using the
HiSeq2000 platform (Illumina, Little Chesterford, UK) to confirm their
mecC gene status and determine their multilocus sequence type (ST). Iso-
lates that were PCR negative for either mecA or mecC were also genome
sequenced to confirmtheirmecgene status. The species identityof isolates
negative by PCR for femBwas tested byassessing their growth andmorph-
ology on Staph Brilliance 24 and MRSA Brilliance 2 agar plates (both Oxoid)
and by PCR to detect nuc.20 spa typing was performed using the primers
spa-1113f (5′-TAA AGA CGA TCC TTC GGT GAG C-3′) and spa-1514r
(5′-CAG CAG TAG TGC CGT TTG CTT-3′) as described by Ridom GmbH
(Wu¨rzburg, Germany).
Results and discussion
PCR (or genome sequence analysis in the case of Addenbrooke’s
Hospital, Cambridge) revealed that 9 isolates out of a total of
2010 MRSA collected weremecCMRSA. ThesemecCMRSA isolates
were largely from screening samples (six isolates), but included
three isolates from skin and soft tissue infections. The remaining
MRSA isolates were allmecA positive, which provides a prevalence
rate ofmecCMRSA among all MRSA collected of 0.45%with a 95%
CI of 0.24%–0.85%. All 2010 isolates were confirmed to be
S. aureus. In the majority of cases this identification was based
onthepresenceof femBasdetectedbyPCRorgenomesequencing.
However, 12 out of the 1675 isolates (0.72%) tested by PCR for
femB were negative for an amplicon and were instead confirmed
to be S. aureus based on their growth on Staph Brilliance and
MRSA Brilliance agar plates and all were positive for nuc. The
basis for the negative femB PCR result is under investigation and
may relate to divergence in the femB primer binding sites.
Indeed, a small number of S. aureus isolates negative for femB
using alternative PCR approaches have been reported previous-
ly.21,22 Two isolates were negative by PCR for both mecA and
mecC, but genome sequencing revealed that they were indeed
mecA positive and carried previously described mecA genes
(NCBI accession numbers FJ390057 and AF411935) with diver-
gence in the primer binding sites used in this study.
Genome sequencing confirmed that each isolate positive for
mecC by PCR encodedmecCwithin an SCCmec type XI. Multilocus
STderived from the genome sequences revealed five different STs
among the nine isolates, including a novel ST, ST2574. Eight of
the isolates belonged to clonal complex (CC) 130, with the remain-
ing isolate belonging to ST425. Five spa types were represented:
Table 1. Contributing hospitals
Clinical microbiology laboratory Location (city and county) First sample date Last sample date Number ofmecA:mecCMRSA
Royal Preston Hospital Preston, Lancashire October 2011 June 2012 335:0
Countess of Chester Hospital Chester, Cheshire November 2011 August 2012 335:0
Nottingham Universities Hospitals Nottingham, Nottinghamshire January 2012 May 2012 333:2
Musgrove Hospital Taunton, Somerset November 2011 May 2012 333:2
Royal Cornwall Hospitals Trust Truro, Cornwall November 2011 July 2012 333:2
Addenbrooke’s Hospital Cambridge, Cambridgeshire April 2012 June 2012 332:3
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t843, t6220, t9280, t11702 and t11706 (Table 2). All mecC MRSA
isolates were resistant to cefoxitin and oxacillin using BSAC guide-
lines for disc diffusion,whileMICs varied from8 to32 mg/L foroxa-
cillin and from 8 to 16 mg/L for cefoxitin (Table 2). Antimicrobial
susceptibility testing using Vitek 2 revealed that resistance to
non-b-lactam antibiotics was rare, the only example being a
single isolate, Ta222, displaying resistance to erythromycin and in-
ducible resistance to clindamycin (Table 2). All nine isolates dis-
played the unusual Vitek 2 resistance profile of being resistant to
cefoxitin, but susceptible to oxacillin. This feature of mecC MRSA,
likely caused by structural differences between the mecA- and
mecC-encoded PBP2a,23 has been described previously and may
behelpful in the identificationofmecCMRSA isolates.24 Thesuscep-
tibility tooxacillinseenusingVitek2 is indisagreementwithouroxa-
cillindiscdiffusion results.mecC-encodedPBP2ahasbeenshownto
be less stable at 378C than at 308C,23 which may explain this
discrepancy, oxacillin disc diffusion being performed at 308C, but
Vitek 2 analysis at 378C. Cefoxitin resistance is presumably still
seen using Vitek 2, even at 378C, because of the higher affinity
mecC-encoded PBP2a has for cefoxitin versus oxacillin.23 All nine
mecC MRSA isolates gave negative results when assayed with
three different commercial PBP2a slide agglutination assays, con-
firming the difficulty of detectingmecCMRSA using this approach.
This is the first formal prospective prevalence study of mecC
MRSAperformed in theUKandthesedataprovideabaselinepreva-
lence for the future surveillance ofmecCMRSA in England. Contin-
uedmonitoring ofmecC is potentially important given the increase
in prevalence ofmecCMRSA reported in Denmark.19 There are few
other data onmecCMRSA prevalence elsewhere, but in Germany a
largemulticentre prospective study identifieda singlemecC isolate
among 1604 tested in 2004–05 and again a single isolate from
1603 tested in 2010–11.10 This indicates a prevalence of 0.06%
with no change between the study periods. In contrast, the preva-
lence in Denmark was both higher and increasing, rising from
1.91% in 2010 to 2.78% in 2011.19 A survey of 565 human MRSA
isolates in Switzerland failed to find any mecC MRSA, indicating
that the prevalence there is lower than in Denmark.13 Clearly,
there are significant and as yet unexplained differences in mecC
MRSA prevalence between different countries, and the recent in-
crease reported in Denmark suggests that it would be prudent to
monitor prevalence in the UK and elsewhere.
None of the hospitals used oxacillin to identify MRSA, which has
been shown to be less reliable than cefoxitin for the detection of
mecC MRSA.25 Nonetheless, it is possible that some mecC MRSA
may have been missed during primary isolation. For instance,
small numbers of mecC MRSA isolates grow poorly on MRSA-
selective agars,9,17 presumably due to their having low cefoxitin/
oxacillin MIC values. An area for future study may be the compari-
sonand standardizationof primary isolationmethods in relation to
mecCMRSA.
The majority of mecC MRSA isolates found in our survey
belonged to CC130, which agrees with the data of Garcia-Alvarez
et al.2 showing that CC130 was the most common lineage
among their retrospective testing for mecC MRSA among human
isolates in theUKandDenmark. BothCC130andST425are thepre-
dominant lineages among mecC MRSA isolates found not only in
humans but also in other host species elsewhere, and genome se-
quencing has provided strong evidence of cross-species transmis-
sionofmecCMRSAbetweenhumansand livestock.26Of thefive spa
types recovered in this study, neither t11702 nor t11706 appear to
have been reported previously amongmecC MRSA, whilst the other
three, t843, t6220 and t9280, have.2,27 There were multiple CCs
belonging to the same spa type and multiple spa types within
the same CC, illustrating the difficulty of inferring CC from spa type
data.
As reported formecCMRSA isolatedelsewhere inEuropeand from
different host species,9,11,15,17,27 resistance to non-b lactamantibio-
tics was uncommon among these EnglishmecCMRSA isolates.
The origins ofmecC MRSA and SCCmec type XI are unclear, but
mecC has also been detected in Staphylococcus stepanovicii,12
Staphylococcus xylosus28 and Staphylococcus sciuri.29 This sug-
gests a possible origin for mecC in coagulase-negative staphylo-
cocci, as proposed for mecA,30,31 and clinical microbiology
laboratories should therefore be aware not only of mecC MRSA
but of the possible occurrence of mecC in other pathogenic
species of methicillin-resistant staphylococci.
Table 2. Characteristics ofmecCMRSA isolates
Isolate Hospital ST CC spa type Vitek profilea Oxacillin MIC (mg/L) Cefoxitin MIC (mg/L) Site of isolation
N35 Nottingham 130 130 t843 benzylpenicillin, cefoxitin 16 16 leg ulcer
N147 Nottingham 130 130 t11702 benzylpenicillin, cefoxitin 24 8 wound swab
Tr8 Truro 2573 130 t843 benzylpenicillin, cefoxitin 16 12 multisite screen
Tr34 Truro 1245 130 t11706 benzylpenicillin, cefoxitin 32 8 multisite screen
Ta222 Taunton 425 425 t11706 benzylpenicillin, cefoxitin,
erythromycin, inducible
resistance to clindamycin
8 8 groin screen
Ta320 Taunton 1245 130 t6220 benzylpenicillin, cefoxitin 32 12 toe wound
Ca155 Cambridge 1245 130 t6220 benzylpenicillin, cefoxitin 24 12 multisite screen
Ca226 Cambridge 2574 (new) 130 t9280 benzylpenicillin, cefoxitin 16 8 multisite screen
Ca322 Cambridge 1245 130 t843 benzylpenicillin, cefoxitin 32 12 multisite screen
aOnly resistances are shown. Resistance to benzylpenicillin, cefoxitin, oxacillin, ciprofloxacin, erythromycin, chloramphenicol, daptomycin, fusidic acid,
gentamicin, linezolid, mupirocin, nitrofurantoin, rifampicin, teicoplanin, tetracycline, tigecycline, trimethoprim, vancomycin and clindamycin was
tested for, as well as inducible resistance to clindamycin.
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